Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.

In a historic first, a therapy developed by Summit Therapeutics beat Merck blockbuster Keytruda in late-stage lung cancer ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).